- **RPG Life Sciences is a pharmaceutical company built on a handful of trusted, decades-old medicines that doctors still prescribe every day - it takes these legacy brands, keeps them relevant with new doses and combinations, and layers on a growing portfolio of modern specialty drugs for chronic diseases. The company began in 1968 as a joint venture with G.D. Searle, became part of the RPG Group, and was renamed RPG Life Sciences in 1999 after G.D. Searle withdrew its India operations. The recurring approach is to own the molecule from start to finish - it makes the active ingredient, formulates the finished pill, and sells it under its own brand to doctors in India while also supplying generic versions to partners abroad, which gives it control over quality, cost and supply.** # Business segments A single integrated pharmaceutical engine with three mutually reinforcing streams - branded domestic formulations that doctors prescribe, international generics supplied to global partners, and the in-house API manufacturing that feeds both. ## 1. Domestic Formulations: the branded-prescription engine that doctors trust **Six legacy brands with over fifty years of clinical history anchor a portfolio that now spans nine therapy areas, from nephrology to oncology, sold through a specialist sales force to India's doctors.** - **Legacy brands are the bedrock** - six "textbook brands" including Azoran, Aldactone, Lomotil and Naprosyn have been prescribed for decades, and the company extends their life by launching new strengths, combinations and dosage forms such as Azoran 75, Aldactone T and Naprosyn+ GEL. - **Immunosuppressants are the specialty stronghold** - the company calls itself a leader in this category, with a portfolio of Azoran, Mofetyl, Arpimune ME and Imunotac that it is building toward a ₹100 crores portfolio with twelve variants and four new customer segments. - **Biosimilars open the next frontier** - a newer line of monoclonal antibodies including HerMab (Trastuzumab) and Adlumab (Adalimumab) takes the company into high-value oncology and autoimmune treatments, sold alongside small-molecule specialty drugs like T-JAKI and Denbri. - **A specialist sales force calls on the right doctors** - the field team targets cardiologists, nephrologists, rheumatologists and oncologists, with specialty productivity reaching ₹16.7 lakhs per representative per month, well above the company-wide average of over ₹6.5 lakhs. - **Digital tools keep doctors engaged** - the proprietary RPGServ platform gives more than one lakh doctors, including over 36,000 specialists, anytime access to curated scientific literature and an AI-powered patient education service, while the RXR 3.0 system tracks every sales call and customer activity. ## 2. International Formulations: the global generics supply arm **The company sells oral solid-dosage generics and branded generics to leading global pharmaceutical players, with a focus on products that are hard to make and have few competitors.** - **Immunosuppressants travel well** - Azathioprine is the flagship export product, and the portfolio also includes branded generics like Azoran, Mofetyl and Arpimune ME sold into nephrology markets across Canada, the UK, Germany, France and Australia. - **Complexity keeps competition low** - the business deliberately targets products that need special manufacturing conditions such as low humidity and low temperature, along with complex generics where fewer rivals can follow. - **Backward integration locks in supply** - because the company makes its own APIs, the international formulations business is not dependent on outside suppliers for its key starting materials, which strengthens its reliability with global customers. ## 3. Active Pharmaceutical Ingredients: the molecule factory that feeds the rest **A niche API business making high-value, low-volume synthetic molecules - primarily immunosuppressants - for both captive use and sale to generic drug makers worldwide.** - **The immunosuppressant basket is the core** - Azathioprine and Mycophenolate Mofetil are the lead APIs, sold alongside a broader catalogue that includes Nicorandil, Haloperidol, Risperidone, Sertraline and others. - **Captive consumption de-risks the formulations business** - the API unit supplies the international formulations arm directly, so the company is not exposed to third-party API price swings or shortages for its own finished-dose products. - **Global customers span regulated and emerging markets** - the API business sells to major pharma and generic companies in Germany, Japan, South Korea, China, Brazil, Mexico, Iran, Egypt and beyond. - **The strategy is shifting toward harder-to-copy molecules** - the company is targeting complex and niche APIs with high entry barriers, including chemistries that are difficult to manufacture and new therapy areas such as GLP-1, while also pursuing capacity expansion and potential acquisitions. - **A dedicated subsidiary is being carved out** - in December 2025 the board approved transferring the API division to a newly incorporated wholly owned subsidiary, RPG Active Pharma Limited, as a going concern, with completion expected by March 2026. # Manufacturing and R&D backbone **Three plants with approvals from advanced-country regulators, plus in-house R&D that develops both the molecule and the finished pill - the infrastructure that makes vertical integration real.** - **Two formulations plants, two different jobs** - the Ankleshwar Unit 1 makes tablets, liquids and powders for domestic and emerging markets, while Unit 2 is built for regulated markets with dedicated lines that handle low-humidity and low-temperature products, holding EU GMP approval from the Hamburg Health Authority. - **One API plant with a dedicated immunosuppressant block** - the Navi Mumbai site has three manufacturing blocks, one of which (MF2) is a dedicated facility for immunosuppressant APIs serving regulated and emerging markets, with approvals from WHO, TGA Australia and PMDA Japan. - **₹140 crores of capex since FY22 has modernised all three plants** - the investment has built facilities with EU, TGA and PMDA approvals, and digital tools now run across manufacturing, including an e-QMS for quality, an e-DMS for documents, biometric retina scanners for equipment access, and IoT-based monitoring of chilling plants and air handling units. - **R&D spans both the pill and the molecule** - the formulations R&D lab develops immediate-release, modified-release and complex generics with a GLP-compliant analytical lab, while the API R&D lab works on niche, low-competition molecules aligned with the company's strategic priorities. - **Regulatory expertise opens doors in advanced markets** - an in-house regulatory team handles submissions to Canada, the UK, the EU and Australia, with eCTD capabilities and integrated project management, and recently secured Health Canada approval for an NSAID drug product and a CEP approval for an immunosuppressant API in Europe. # Group structure and partners **A single listed entity within the RPG Group, now creating its first subsidiary to house the API business, with captive solar power investments to run the plants.** - RPG Life Sciences is part of the RPG Group, a diversified conglomerate with over 31,000 employees, a presence in more than 135 countries, and annual gross revenues of USD 5.2 billion spanning infrastructure, tyres, IT, pharmaceuticals, energy and plantations. - Until recently the company had no subsidiaries, joint ventures or associates - it operated as a single legal entity from its Mumbai head office. - In December 2025 it incorporated RPG Active Pharma Limited as a wholly owned subsidiary to receive the API business as a going concern via a business transfer agreement. - The company has invested ₹1.01 crores in Sunpound Solar Private Limited, a special-purpose vehicle for captive solar power generation at the Navi Mumbai API plant, and has signed a power purchase agreement with First Energy 11 Private Limited for a wind-solar hybrid plant to supply the Ankleshwar formulation plant, with an equity investment of up to ₹1.5 crores.